Utidelone before surgery for high-risk breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new chemotherapy drug called utidelone, given before surgery for early high-risk or locally advanced breast cancer. The goal is to see if this drug can shrink tumors and improve outcomes. It may be a treatment option for people who meet the specific criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70 and have just been diagnosed with breast cancer that has not spread to other organs.
- Your tumor is stage II or III (meaning it is at least 2 cm or has spread to nearby lymph nodes).
- You have not had any prior cancer treatment (except for cured cervical or skin cancers).
- Your heart function is normal (ejection fraction ≥ 55%) and your blood counts and liver/kidney function are within acceptable ranges.
- You are not pregnant and are willing to use effective birth control during the study and for 6 months after.
- You have no significant nerve damage (neuropathy) or serious heart/blood vessel problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, utidelone and cisplatin, given before surgery to shrink breast tumors. The goal is to make surgery more effective and improve outcomes.
This study tests whether adding utidelone (an investigational drug) to capecitabine (a standard chemo pill) after surgery can reduce the chance of breast cancer returning in patients with triple-negative breast cancer who still had cancer cells after neoadjuvant chemotherapy. Participation could help improve your treatment plan to lower the risk of recurrence.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a new combination of two oral medications—imlunestrant (a hormone therapy) and abemaciclib (a drug that blocks cancer growth)—given before surgery. The goal is to see if these drugs can shrink the tumor, using your tumor's growth rate (Ki67) after two weeks of treatment to guide further therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.